

# Klaus G Parhofer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2333659/publications.pdf>

Version: 2024-02-01

67  
papers

11,038  
citations

61945

43  
h-index

102432

66  
g-index

70  
all docs

70  
docs citations

70  
times ranked

11407  
citing authors

#	ARTICLE	IF	CITATIONS
1	New targets for treating hypertriglyceridemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, Publish Ahead of Print, .	1.2	1
2	Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. , 2022, 237, 108172.		18
3	Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia). <i>PLoS ONE</i> , 2022, 17, e0265838.	1.1	8
4	Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 3810.	1.0	2
5	Postprandial Lipid Metabolism in Normolipidemic Subjects and Patients with Mild to Moderate Hypertriglyceridemia: Effects of Test Meals Containing Saturated Fatty Acids, Mono-Unsaturated Fatty Acids, or Medium-Chain Fatty Acids. <i>Nutrients</i> , 2021, 13, 1737.	1.7	10
6	Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 74.	2.0	0
7	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 50-67.	5.5	114
8	Clinical review on triglycerides. <i>European Heart Journal</i> , 2020, 41, 99-109c.	1.0	286
9	Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. <i>European Heart Journal Supplements</i> , 2020, 22, J21-J33.	0.0	7
10	Evaluation of the effect of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	2.9	155
11	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	2.9	205
12	The Diagnosis and Treatment of Hypertriglyceridemia. <i>Deutsches Arzteblatt International</i> , 2019, 116, 825-832.	0.6	50
13	Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 267-276.	4.3	81
14	Effects of a cluster-randomized school-based prevention program on physical activity and microvascular function (JuvenTUM 3). <i>Atherosclerosis</i> , 2018, 278, 73-81.	0.4	16
15	Diagnostic algorithm for familial chylomicronemia syndrome. <i>Atherosclerosis Supplements</i> , 2017, 23, 1-7.	1.2	94
16	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. <i>PLoS ONE</i> , 2017, 12, e0177501.	1.1	37
17	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. <i>European Heart Journal</i> , 2016, 37, 3588-3595.	1.0	174
18	Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 285-294.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Lipoprotein apheresis to treat elevated lipoprotein (a). Journal of Lipid Research, 2016, 57, 1751-1757.	2.0	78
20	Whole-Body MR Imaging Including Angiography: Predicting Recurrent Events in Diabetics. European Radiology, 2016, 26, 1420-1430.	2.3	9
21	The Treatment of Disorders of Lipid Metabolism. Deutsches A&#x0308;rztblatt International, 2016, 113, 261-8.	0.6	55
22	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes and Metabolism Journal, 2015, 39, 353.	1.8	272
23	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atherosclerosis Supplements, 2015, 18, 109-111.	1.2	37
24	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. European Journal of Preventive Cardiology, 2015, 22, 849-854.	0.8	60
25	The Diabetes Risk Phenotype of Young Women With Recent Gestational Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E910-E918.	1.8	44
26	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644
27	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
28	Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clinical Endocrinology, 2014, 80, 47-56.	1.2	168
29	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	0.6	98
30	Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?. Artificial Organs, 2014, 38, 135-141.	1.0	70
31	Diabetic dyslipidemia. Metabolism: Clinical and Experimental, 2014, 63, 1469-1479.	1.5	344
32	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	0.8	316
33	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology, 2014, 2, 655-666.	5.5	473
34	Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: A randomized controlled cross-over clinical trial. Metabolism: Clinical and Experimental, 2014, 63, 382-391.	1.5	75
35	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
36	Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evidence, 2012, 7, 29.	4.7	32

#	ARTICLE	IF	CITATIONS
37	PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitusâ€”Study design. <i>Primary Care Diabetes</i> , 2011, 5, 231-239.	0.9	39
38	High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor- $\beta$ Target Genes in Patients With the Metabolic Syndrome. <i>Hypertension</i> , 2011, 58, 725-732.	1.3	31
39	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010, 21, 492-498.	1.2	95
40	Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). <i>American Journal of Cardiology</i> , 2010, 105, 667-671.	0.7	60
41	Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet. <i>Diabetes</i> , 2010, 59, 2898-2903.	0.3	89
42	Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. <i>Vascular Health and Risk Management</i> , 2009, 5, 901.	1.0	20
43	Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques. <i>PLoS ONE</i> , 2009, 4, e4733.	1.1	55
44	Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. <i>European Journal of Endocrinology</i> , 2009, 161, 339-344.	1.9	257
45	Pericardial Adipose Tissue Determined by Dual Source CT Is a Risk Factor for Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 781-786.	1.1	243
46	Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. <i>Nature Reviews Cardiology</i> , 2009, 6, 229-239.	6.1	206
47	Systemic Cardiovascular Complications in Patients With Long-Standing Diabetes Mellitus. <i>Investigative Radiology</i> , 2009, 44, 242-250.	3.5	44
48	Adipokines and Insulin Resistance. <i>Molecular Medicine</i> , 2008, 14, 741-751.	1.9	673
49	CXCL16 is a surrogate marker of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 283-288.	0.6	26
50	Resistin is an inflammatory marker of inflammatory bowel disease in humans. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 1070-1074.	0.8	128
51	Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 599-604.	1.5	29
52	The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1149-1154.	1.5	81
53	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
54	Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2006, 45, 887-891.	1.8	48

#	ARTICLE	IF	CITATIONS
55	PROGNOSTIC VALUE OF INTERLEUKIN 6, PROCALCITONIN, AND C-REACTIVE PROTEIN LEVELS IN INTENSIVE CARE UNIT PATIENTS DURING FIRST INCREASE OF FEVER. <i>Shock</i> , 2006, 26, 10-12.	1.0	90
56	Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies. <i>Journal of Lipid Research</i> , 2006, 47, 1620-1630.	2.0	47
57	Long-term reduction of C-reactive protein concentration by regular LDL apheresis. <i>Atherosclerosis</i> , 2004, 174, 151-156.	0.4	42
58	Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. <i>Atherosclerosis</i> , 2004, 175, 325-331.	0.4	44
59	Comparison of current guidelines for primary prevention of coronary heart disease. <i>Journal of General Internal Medicine</i> , 2003, 18, 190-195.	1.3	30
60	Efficacy and Safety of a New Whole-blood Low-density Lipoprotein Apheresis System (Liposorber D) in Severe Hypercholesterolemia. <i>Artificial Organs</i> , 2003, 27, 1116-1122.	1.0	53
61	Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. <i>Journal of Lipid Research</i> , 2003, 44, 1192-1198.	2.0	45
62	Bowel Habits and Bile Acid Malabsorption in The Months After Cholecystectomy. <i>American Journal of Gastroenterology</i> , 2002, 97, 1732-1735.	0.2	78
63	Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 983-988.	1.5	40
64	Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. <i>American Journal of Cardiology</i> , 2001, 87, 44-48.	0.7	111
65	Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4224-4230.	1.8	54
66	The Prevention Education Program (PEP). A Prospective Study of the Efficacy of Family-Oriented Life Style Modification in the Reduction of Cardiovascular Risk and Disease. <i>Journal of Clinical Epidemiology</i> , 1999, 52, 791-800.	2.4	53
67	Apoprotein B-100 Production Is Decreased in Subjects Heterozygous for Truncations of Apoprotein B. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 71-80.	1.1	65